SH3D19 encodes Eve-1 (EBP), a cytoplasmic protein containing multiple SH3 domains that regulates EGFR-ligand shedding and cellular transformation. Mechanistically, SH3D19/Eve-1 functions as a positive regulator of ADAM-mediated ectodomain proteolysis, as demonstrated by reduced shedding of EGFR ligands (proHB-EGF, pro-TGF-α, promorphiregulin, proepiregulin) upon Eve-1 knockdown 1. The protein suppresses Ras-induced cellular transformation through its RAS-suppressive functions, which can be inhibited by nuclear recruitment 2. SH3D19 also plays a role in cytoskeletal organization and cell morphology regulation. Clinically, SH3D19 has been implicated in hematologic malignancies. It was identified as a novel RUNX1 translocation partner in acute myeloid leukemia (AML), where t(4;21) translocations create a RUNX1-EBP fusion protein that retains RUNX1's DNA-binding domain while nuclear-localizing the chimeric protein, potentially inhibiting EBP's RAS-suppressive functions 2. SH3D19 has also been identified in submicroscopic deletions/translocations in primary myelofibrosis 3, suggesting broader involvement in myeloid malignancies. Additionally, SH3D19 expression is downregulated during oocyte maturation 4, indicating developmental roles beyond transformation suppression.